ELIMINATE

Closed

ANZ 1401: ELIMINATE

Treatment of breast cancer often involves surgery first which may be followed by additional treatment. However, neoadjuvant therapy (treatment before surgery) may be given when the breast cancer is large or complex in an attempt to shrink the cancer, which may potentially avoid the need for more extensive surgery associated with mastectomy and reconstruction. The ELIMINATE clinical trial will investigate if giving neoadjuvant hormone therapy and chemotherapy at the same time is more effective than neoadjuvant chemotherapy alone at shrinking the breast cancer before surgery.

0

INTERNATIONAL

Total number of trial

participants internationally

134

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

24

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

ELIMINATE TRANSLATIONAL RESEARCH SAMPLES

Randomised phase II trial of neoadjuvant chemotherapy +/- concurrent aromatase inhibitor endocrine therapy to down-stage large oestrogen receptor positive breast cancer (ACTRN12614000515695)

ELIMINATE PUBLICATIONS

2022

Randomised trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials Group ANZ 1401 ELIMINATE trial.

Murray N, Francis P, Zdenkowski N, Wilcken N, Boyle F, Gebski V, Tiley S M, Gilham L, Dawson S-J, Loi S, Redfern A D, Lombard J, Spillane A, Shadbolt C, Badger H. Annals of Oncology. 2022; 33(S3):S164 – S165, ESMO Abstract #90MO, Abstract

ELIMINATE